Table 1.
Study population characteristics after matching
| Level | Overall | SARS CoV-2-negative | SARS CoV-2-positive | PASC | |
|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | ||
| n | 14 399 | 6545 | 6545 | 1309 | |
| Age at cohort entrance (%) | <1 | 363 (2.5) | 165 (2.5) | 165 (2.5) | 33 (2.5) |
| 1–4 | 1309 (9.1) | 595 (9.1) | 595 (9.1) | 119 (9.1) | |
| 5–11 | 4708 (32.7) | 2140 (32.7) | 2140 (32.7) | 428 (32.7) | |
| 12–15 | 4213 (29.3) | 1915 (29.3) | 1915 (29.3) | 383 (29.3) | |
| 16–20 | 3806 (26.4) | 1730 (26.4) | 1730 (26.4) | 346 (26.4) | |
| Sex (%) | Female | 7903 (54.9) | 3544 (54.1) | 3640 (55.6) | 719 (54.9) |
| Male | 6496 (45.1) | 3001 (45.9) | 2905 (44.4) | 590 (45.1) | |
| Race/ethnicity (%) | Non-Hispanic Asian/PI | 519 (3.6) | 245 (3.7) | 228 (3.5) | 46 (3.5) |
| Non-Hispanic Black/AA | 1425 (9.9) | 623 (9.5) | 674 (10.3) | 128 (9.8) | |
| Hispanic | 1698 (11.8) | 748 (11.4) | 793 (12.1) | 157 (12.0) | |
| Multiple | 593 (4.1) | 258 (3.9) | 282 (4.3) | 53 (4.0) | |
| Other/Unknown | 1275 (8.9) | 540 (8.3) | 607 (9.3) | 128 (9.8) | |
| Non-Hispanic White | 8889 (61.7) | 4131 (63.1) | 3961 (60.5) | 797 (60.9) | |
| Cohort entry month (%) | March 2020 | 77 (0.5) | 35 (0.5) | 35 (0.5) | 7 (0.5) |
| April 2020 | 132 (0.9) | 60 (0.9) | 60 (0.9) | 12 (0.9) | |
| May 2020 | 66 (0.5) | 30 (0.5) | 30 (0.5) | 6 (0.5) | |
| June 2020 | 110 (0.8) | 50 (0.8) | 50 (0.8) | 10 (0.8) | |
| July 2020 | 121 (0.8) | 55 (0.8) | 55 (0.8) | 11 (0.8) | |
| August 2020 | 110 (0.8) | 50 (0.8) | 50 (0.8) | 10 (0.8) | |
| September 2020 | 165 (1.1) | 75 (1.1) | 75 (1.1) | 15 (1.1) | |
| October 2020 | 198 (1.4) | 90 (1.4) | 90 (1.4) | 18 (1.4) | |
| November 2020 | 341 (2.4) | 155 (2.4) | 155 (2.4) | 31 (2.4) | |
| December 2020 | 341 (2.4) | 155 (2.4) | 155 (2.4) | 31 (2.4) | |
| January 2021 | 429 (3.0) | 195 (3.0) | 195 (3.0) | 39 (3.0) | |
| February 2021 | 242 (1.7) | 110 (1.7) | 110 (1.7) | 22 (1.7) | |
| March 2021 | 352 (2.4) | 160 (2.4) | 160 (2.4) | 32 (2.4) | |
| April 2021 | 385 (2.7) | 175 (2.7) | 175 (2.7) | 35 (2.7) | |
| May 2021 | 286 (2.0) | 130 (2.0) | 130 (2.0) | 26 (2.0) | |
| June 2021 | 385 (2.7) | 175 (2.7) | 175 (2.7) | 35 (2.7) | |
| July 2021 | 418 (2.9) | 190 (2.9) | 190 (2.9) | 38 (2.9) | |
| August 2021 | 671 (4.7) | 305 (4.7) | 305 (4.7) | 61 (4.7) | |
| September 2021 | 1111 (7.7) | 505 (7.7) | 505 (7.7) | 101 (7.7) | |
| October 2021 | 770 (5.3) | 350 (5.3) | 350 (5.3) | 70 (5.3) | |
| November 2021 | 957 (6.6) | 435 (6.6) | 435 (6.6) | 87 (6.6) | |
| December 2021 | 1584 (11.0) | 720 (11.0) | 720 (11.0) | 144 (11.0) | |
| January 2022 | 1837 (12.8) | 835 (12.8) | 835 (12.8) | 167 (12.8) | |
| February 2022 | 1023 (7.1) | 465 (7.1) | 465 (7.1) | 93 (7.1) | |
| March 2022 | 858 (6.0) | 390 (6.0) | 390 (6.0) | 78 (6.0) | |
| April 2022 | 693 (4.8) | 315 (4.8) | 315 (4.8) | 63 (4.8) | |
| May 2022 | 737 (5.1) | 335 (5.1) | 335 (5.1) | 67 (5.1) | |
| Institution (%) | A | 1116 (7.8) | 562 (8.6) | 453 (6.9) | 101 (7.7) |
| B | 1507 (10.5) | 664 (10.1) | 686 (10.5) | 157 (12.0) | |
| C | 2724 (18.9) | 1275 (19.5) | 1187 (18.1) | 262 (20.0) | |
| D | 469 (3.3) | 212 (3.2) | 218 (3.3) | 39 (3.0) | |
| E | 1058 (7.3) | 429 (6.6) | 541 (8.3) | 88 (6.7) | |
| F | 801 (5.6) | 333 (5.1) | 391 (6.0) | 77 (5.9) | |
| G | 1130 (7.8) | 525 (8.0) | 495 (7.6) | 110 (8.4) | |
| H | 2670 (18.5) | 1235 (18.9) | 1201 (18.3) | 234 (17.9) | |
| I | 2924 (20.3) | 1310 (20.0) | 1373 (21.0) | 241 (18.4) | |
| Test location (%) | ED | 2087 (14.5) | 863 (13.2) | 1055 (16.1) | 169 (12.9) |
| Inpatient | 1446 (10.0) | 627 (9.6) | 695 (10.6) | 124 (9.5) | |
| Other/unknown | 372 (2.6) | 139 (2.1) | 189 (2.9) | 44 (3.4) | |
| Outpatient office | 6702 (46.5) | 3130 (47.8) | 2940 (44.9) | 632 (48.3) | |
| Outpatient: test only | 3792 (26.3) | 1786 (27.3) | 1666 (25.5) | 340 (26.0) | |
| PMCA index (%) | Nonchronic | 6297 (43.7) | 2802 (42.8) | 2917 (44.6) | 578 (44.2) |
| Chronic noncomplex | 5605 (38.9) | 2572 (39.3) | 2535 (38.7) | 498 (38.0) | |
| Complex chronic | 2497 (17.3) | 1171 (17.9) | 1093 (16.7) | 233 (17.8) |